STOCK TITAN

Twist Bioscience to Present at the UBS MedTech, Tools and Genomics Summit 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) announced that Patrick Finn, Ph.D., will participate in the UBS MedTech, Tools and Genomics Summit 2023 panel on August 15. The panel will discuss Innovation Across Drug Discovery, Molecule Synthesis, & Precision Medicine. The event will be webcast live and available for replay on the company's investor relations website.
Positive
  • None.
Negative
  • None.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Patrick Finn, Ph.D., president and COO of Twist Bioscience, will participate in the Innovation Across Drug Discovery, Molecule Synthesis, & Precision Medicine panel at the UBS MedTech, Tools and Genomics Summit 2023 on Tuesday, August 15 at 2:00 p.m. Pacific Time.

The panel will be webcast live and can be accessed by visiting the “Investor Calendar” page of the investor relations section of the company's website here. A replay of the presentation will be archived for a period of 30 days following the conclusion of the live events.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on Twitter | Facebook | LinkedIn | YouTube

For Twist Bioscience:

Angela Bitting

SVP, Corporate Affairs

925-202-6211

abitting@twistbioscience.com

Source: Twist Bioscience Corporation

The company mentioned is Twist Bioscience Corporation (NASDAQ: TWST).

Patrick Finn will participate in the UBS MedTech, Tools and Genomics Summit 2023 panel.

The panel will take place on Tuesday, August 15 at 2:00 p.m. Pacific Time.

The panel can be accessed by visiting the 'Investor Calendar' page of the investor relations section of Twist Bioscience's website.

Yes, a replay of the presentation will be archived for a period of 30 days following the conclusion of the live events.
Twist Bioscience Corp

NASDAQ:TWST

TWST Rankings

TWST Latest News

TWST Stock Data

Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Health Technology, Biotechnology
US
South San Francisco

About TWST

at twist bioscience, our expertise is synthetic dna. we have developed a proprietary semiconductor-based synthetic dna manufacturing process featuring a 10,000-well silicon platform capable of producing synthetic biology tools, such as oligonucleotides, genes, pathways, chassis and genomes. by synthesizing dna on silicon instead of on traditional 96-well plastic plates, our platform overcomes the current inefficiencies of synthetic dna production, and enables cost-effective, rapid, high-quality and high throughput synthetic gene production. the twist bioscience platform has the potential to greatly accelerate the development of personalized medicine, sustainable chemical production, improved agriculture production as well as new applications such as in vivo diagnostics, biodetection and data storage. for more information, please visit www.twistbioscience.com .